Irsamla

Vortioxetine, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as an oral pharmaceutical product for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Vortioxetine acts on the serotonergic system and is primarily used for depressive disorders.

- Major depressive disorder: reduces depressive symptoms in adult patients. - Persistent depressive disorder: helps maintain mood stability over the long term. - Depressive episodes associated with major depressive disorder: improves overall functioning and quality of life.

Vortioxetine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Headache - Dizziness - Dry mouth - Constipation - Decreased sexual desire or performance

Serious or Rare Side Effects: - Suicidal thoughts or behavior - Serotonin syndrome (e.g., agitation, hyperthermia, muscle rigidity) - Severe hypertension - Hyponatremia - Anaphylactic or severe allergic reaction - QT interval prolongation

When prescribing Vortioxetine, clinicians should consider several safety measures.

- Psychiatric assessment: evaluate baseline mood and suicidal risk before initiation. - Monitor for worsening depression or emergent suicidal ideation during treatment. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Hepatic impairment: use with caution and consider dose adjustment. - Concomitant MAO inhibitors: avoid use within 14 days of each other. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Vortioxetine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Other serotonergic agents (SSRIs, SNRIs, tramadol, linezolid, triptans): may precipitate serotonin toxicity. - St. John’s wort: potentiates serotonergic effects.

Moderate Interactions (Monitor Closely): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase vortioxetine exposure. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma concentrations. - NSAIDs or anticoagulants: monitor for increased bleeding risk.